Comparative Pharmacology
Head-to-head clinical analysis: CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE versus PARICALCITOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE versus PARICALCITOL.
CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE vs PARICALCITOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Calcipotriene is a synthetic vitamin D3 analog that binds to vitamin D receptors, regulating cell proliferation and differentiation. Betamethasone dipropionate is a corticosteroid that reduces inflammation by inducing phospholipase A2 inhibitory proteins (lipocortins), inhibiting arachidonic acid release, and decreasing prostaglandin and leukotriene synthesis.
Paricalcitol is a synthetic vitamin D analog that binds to the vitamin D receptor (VDR) in target tissues, including the parathyroid glands, kidneys, and intestines. It selectively activates VDR to suppress parathyroid hormone (PTH) secretion, reduce parathyroid cell proliferation, and modulate calcium and phosphate homeostasis with lower calcemic and phosphatemic effects compared to calcitriol.
Apply once daily to affected areas of skin, not exceeding 100 g/week or 30 mL/day. Do not use under occlusive dressings.
0.04 to 0.1 mcg/kg intravenously bolus no more frequently than every other day during dialysis, or 1 to 4 mcg orally once daily.
None Documented
None Documented
Clinical Note
moderateParicalcitol + Digoxin
"The risk or severity of adverse effects can be increased when Paricalcitol is combined with Digoxin."
Clinical Note
moderateParicalcitol + Hydrochlorothiazide
"Paricalcitol may increase the hypercalcemic activities of Hydrochlorothiazide."
Clinical Note
moderateParicalcitol + Bendroflumethiazide
"Paricalcitol may increase the hypercalcemic activities of Bendroflumethiazide."
Clinical Note
moderateParicalcitol + Methyclothiazide
Calcipotriene: 12-24 hours; betamethasone dipropionate: 4-6 hours (parent), 3-5 hours (active metabolite betamethasone 17-propionate).
Terminal elimination half-life is approximately 5-7 hours in healthy subjects, but may be prolonged to 14-20 hours in patients with renal impairment.
Calcipotriene: renal elimination of metabolites; betamethasone dipropionate: primarily renal (70%) and biliary/fecal (30%) as metabolites.
Primarily fecal (74%) via hepatobiliary excretion; renal elimination accounts for approximately 16% as unchanged drug.
Category C
Category C
Vitamin D Analog
Vitamin D Analog
"Paricalcitol may increase the hypercalcemic activities of Methyclothiazide."